Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
sábado, octubre 03
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Jazz Pharmaceuticals PLC
JAZZ
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$235.67
2.66
1.14%
Últ. Act.: Oct 2, 4:00 PM
$235.67
2.66
1.14%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Privacy Manager
Jazz Pharmaceuticals Financials
Jazz Pharmaceuticals (JAZZ) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
These Analysts Increase Their Forecasts On Jazz Pharmaceuticals Following Q2 Results
Jazz Pharmaceuticals (JAZZ) reported Q2 sales above estimates and raised its FY26 sales guidance. Analysts have mixed opinions, with some raising price targets. Consider buying JAZZ stock.
Avi Kapoor
PRO
Jazz Pharmaceuticals Raises FY2026 Sales Guidance from $4.250B-$4.500B to $4.600B-$4.750B vs $4.517B Est
Jazz Pharmaceuticals (NASDAQ:JAZZ) raises FY2026 sales outlook from $4.250 billion-$4.500 billion to $4.600 billion-$4.750 billion vs $4.517 billion estimate.
Benzinga Newsdesk
PRO
Jazz Pharmaceuticals Q2 Adj. EPS $5.71 Misses $6.18 Estimate, Sales $1.208B Beat $1.115B Estimate
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported quarterly earnings of $5.71 per share which missed the analyst consensus estimate of $6.18 by 7.61 percent. This is a 169.21 percent increase over losses of $(8.25) per share
Benzinga Newsdesk
PRO
Jazz Pharmaceuticals Affirms FY2026 Sales Guidance of $4.250B-$4.500B vs $4.445B Est
Jazz Pharmaceuticals (NASDAQ:JAZZ) affirms FY2026 sales outlook from $4.250 billion-$4.500 billion to $4.250 billion-$4.500 billion vs $4.445 billion estimate.
Benzinga Newsdesk
PRO
Jazz Pharmaceuticals Q1 Adj. EPS $6.34 Beats $4.57 Estimate, Sales $1.609B Beat $976.563M Estimate
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported quarterly earnings of $6.34 per share which beat the analyst consensus estimate of $4.57 by 38.73 percent. This is a 277.38 percent increase over earnings of $1.68 per share
Benzinga Newsdesk
Earnings Scheduled For May 5, 2026
Benzinga Insights
